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Abstract
Background: Various pivotal stages in smoking behavior can be identified,
including initiation, conversion from experimenting to established use, development of tolerance, and cessation. Previous studies have shown high heritability
for age of smoking initiation and cessation; however, time-to-event genomewide association studies aiming to identify underpinning genes that accelerate
or delay these transitions are missing to date. Methods: We investigated which
single nucleotide polymorphisms (SNPs) across the whole genome contribute
to the hazard ratio of transition between different stages of smoking behavior
by performing time-to-event analyses within a large Finnish twin family cohort
(N = 1962), and further conducted mediation analyses of plausible intermediate
traits for significant SNPs. Results: Genome-wide significant signals were
detected for three of the four transitions: (1) for smoking cessation on 10p14
(P = 4.47e-08 for rs72779075 flanked by RP11-575N15 and GATA3), (2) for
tolerance on 11p13 (P = 1.29e-08 for rs11031684 in RP1-65P5.1), mediated by
smoking quantity, and on 9q34.12 (P = 3.81e-08 for rs2304808 in FUBP3),
independent of smoking quantity, and (3) for smoking initiation on 19q13.33
(P = 3.37e-08 for rs73050610 flanked by TRPM4 and SLC6A16) in analysis
adjusted for first time sensations. Although our top SNPs did not replicate,
another SNP in the TRPM4-SLC6A16 gene region showed statistically significant association after region-based multiple testing correction in an independent Australian twin family sample. Conclusion: Our results suggest that the
functional effect of the TRPM4-SLC6A16 gene region deserves further investigation, and that complex neurotransmitter networks including dopamine and glutamate may play a critical role in smoking initiation. Moreover, comparison of
these results implies that genetic contributions to the complex smoking behavioral phenotypes vary among the transitions.
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Introduction
Various pivotal stages can be identified in an individual’s
smoking history, including smoking initiation, conversion
from experimenting to established use, development of

tolerance, and cessation. Each transition is likely influenced by environmental and genetic factors, some of
which are common to all steps, and others that are
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specific. Modest to high heritability has been reported for
the majority of smoking behavior phenotypes (Madden
et al. 2004; Horimoto et al. 2012; Loukola et al. 2014),
with a study of Finnish adult twins reporting heritability
estimates of 0.59 in males and 0.36 in females for age at
initiation of smoking (Broms et al. 2006).
Nicotine is the main psychoactive compound in
tobacco, and exerts its functions by binding to nicotinic
acetylcholine receptors (nAChR). Genome-wide association study (GWAS) meta-analyses have robustly reported
that the CHRNA5-CHRNA3-CHRNB4 nAChR gene cluster on 15q25 and the CHRNB3-CHRNA6 region on
8p11.21 are associated with smoking quantity (measured
by cigarettes per day, CPD) and nicotine dependence
(ND) (measured by the Fagerström Test for Nicotine
Dependence, FTND (Heatherton et al. 1991)) (Liu et al.
2010; The Tobacco and Genetics Consortium 2010; Thorgeirsson et al. 2010). However, less than 1% of the variance in the amount smoked is explained by alleles of
these genes, with an average effect per allele of one CPD.
Age of onset phenotypes have been utilized in some targeted studies of nAChR genes. Variants in the CHRNA5CHRNA3-CHRNB4 gene cluster are shown to predict a
later age of smoking cessation (Chen et al. 2012), and the
effect of a functional CHRNA5 variant (rs16969968) on
smoking quantity is reported to be stronger in early-onset
smokers than in late-onset smokers (Hartz et al. 2012).
Further, a genetic risk score composed of CHRNA5CHRNA3-CHRNB4 and CYP2A6 (encoding the main
metabolic enzyme for nicotine) variants highlighted in
large CPD GWAS meta-analyses (Liu et al. 2010; The
Tobacco and Genetics Consortium 2010; Thorgeirsson
et al. 2010) was unrelated to smoking initiation, but associated with progression to heavy smoking and ND (Belsky
et al. 2013).
Several GWAS have targeted smoking initiation (Vink
et al. 2009; The Tobacco and Genetics Consortium 2010;
Thorgeirsson et al. 2010; Siedlinski et al. 2011; Argos
et al. 2014) or cessation (The Tobacco and Genetics Consortium 2010; Siedlinski et al. 2011; Argos et al. 2014)
with phenotypes dichotomized into ever versus never or
used as quantitative age of onset phenotypes. Only the
large GWAS meta-analysis of the Tobacco and Genetics
Consortium yielded signals in tyrosine kinase and
dopamine signaling pathway genes that genome-wide
significantly associated with smoking initiation (never vs.
ever smokers) and smoking cessation (former vs. current
smokers), respectively (The Tobacco and Genetics Consortium 2010). Time-to-event analysis is more powerful than
analysis of binary traits or transformed quantitative phenotypes because it incorporates information of follow-up
time span and allows for censoring. There is a huge gap in
understanding the contribution of an associating variant
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to a specific trait. Causal mediation analysis has been used
to improve the understanding of the mechanisms underlying detected associations (Jiang et al. 2013; Liu et al.
2013). The estimation of mediation effects in the context
of survival models has been discussed in previous literature (Lange and Hansen 2011; VanderWeele 2011; Nemes
et al. 2013). Smoking behavior is likely influenced by a
variety of additional factors besides the function of nicotinic receptors and nicotine metabolism, such as psychiatric disorders (e.g., schizophrenia, depression) and
somatic consequences of smoking (e.g., bronchitis, chronic
obstructive pulmonary disease). Understanding the mechanisms underlying the progression of smoking behavior
could facilitate the development of targeted cessation
pharmacotherapies and interventions.
In this study, we investigated which SNPs across the
whole genome contribute to the speed of transition
between different stages of smoking behavior by performing time-to-event analyses within a large Finnish twin
family cohort (N = 1962). We tracked and elaborately
recorded smoking history by detailed interviews. We
adopted time-to-event random effects models to examine
the rate at which the smokers proceed to the next stage,
and incorporated a kinship matrix to account for the
family structure. Specifically, we tested whether genetic
variants are associated with a younger age at smoking
initiation, speed of transition to daily smoking
(dichotomized into rapid vs. slow progression), speed of
transition from daily smoking to the period of heaviest
smoking, and earlier quitting from smoking. When performing association analyses, we considered plausible
intermediate traits as covariates. We then investigated
whether the independent variable, that is, a SNP, affects
the outcome independently or influences the mediators,
which in turn affects the outcome.

Materials and Methods
Sample
Data collection has been described in previous publications (Broms et al. 2007; Loukola et al. 2014). Briefly, subjects were ascertained from the Finnish Twin Cohort study
encompassing 35,834 twins born in 1938–1957. Twin pairs
concordant for smoking were recruited, along with their
family members (mostly siblings). Altogether 1962 subjects
(mean age 56.2  8.3, 50.9% men) from 734 families were
included in this study, consisting of 858 subjects from 429
full dizygotic (DZ) pairs, 146 additional DZ subjects (one
co-twin per pair), 131 monozygotic (MZ) subjects (one
co-twin per pair), 19 twin subjects (unknown zygosity)
without co-twins, 681 siblings (brothers and sisters), and
127 parents (one parent per family). All the subjects had
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initiated smoking and smoked on average 15 CPD. Altogether 880 subjects were successful quitters defined by selfreported abstinence of at least 6 months at the time of the
interview. Written informed consent was obtained from
all subjects who were interviewed and/or gave DNA samples before the beginning of the studies. The collection of
the informed consent as well as blood samples followed
the recommendations given in the Declaration of Helsinki
and its amendments. Data collection was approved by the
hospital district of Helsinki and Uusimaa, the ethical committee for epidemiology and public health (HUS 136/E3/
01). A flowchart of the overall study design is shown in
Figure 1.

Family-Based GWAS on Smoking Progression Stages

For replication of the detected associations, we utilized an
independent Australian twin family sample (NAGOZALC, N = 1884, N = 3389, and N = 2723, for initiation, tolerance, and cessation analyses, respectively). A
brief sample description is presented in the Table S1;
detailed sample description has been previously published
elsewhere (Heath et al. 2011).

through structured telephone interviews, as previously
described (Loukola et al. 2014). Questions used to inquire
the several milestones in smoking behavior are presented in
Table 1. We constructed four time-to-event phenotypic
variables based on the transitions measured in years
between progressive smoking states: (1) smoking initiation
(years from birth to the age of smoking the first cigarette),
(2) persistent smoking (years from the age of smoking the
first cigarette to the age of daily smoking), (3) tolerance
(years from the age of daily smoking to the age when the
heaviest smoking started), and (4) cessation (years from the
age of daily smoking to the age of successful quitting). For
smoking cessation, we defined continuous abstinence of
more than 6 months as successful quitting, as previously
suggested (Hughes et al. 2003), and those individuals still
smoking by the time of the interview were treated as censored. We excluded subjects (N = 70) abstinent for less
than 6 months prior to the interview because their cessation status cannot be deduced. Further, we excluded 55
subjects who reported quitting due to health reasons, as
genetic background may have little or no effect on quitting
success in such a situation. The basic characteristics of the
data used in the analyses are listed in Table 2.

Phenotypes

Evaluation of Covariates

Detailed information on the evolution of smoking behavior
as well as relevant covariates was retrospectively collected

We first performed genome-wide time-to-event analyses
for each of the transitions with only sex as a covariate. As

Replication sample

Figure 1. A flowchart of the study design. Circle: smoking stage; orange rectangle: milestone in smoking behavior; green rectangle: considered
covariates. Numbers indicate the number of subject included in the analysis with sex as a covariate for each transition (for Smoking initiation also
birth year was included).
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Table 1. Questions used to assess the milestones and potential confounders of smoking behavior.

Smoking state
Age of smoking the first
cigarette
Age when daily smoking
started
Age when the heaviest
smoking started
Age of successful quitting

Covariate
Cigarettes per day (CPD)

Maximum cigarettes per day
(max CPD)
Positive first time sensations

Negative first time sensations

Fagerström Test for Nicotine
Dependence (FTND) Score
Years between the first and
second cigarettes

Diagnostic and Statistical
Manual of Mental Disorders,
4th Edition (DSM-IV) nicotine
withdrawal symptoms

Questions used

Mean (SD)

“How old were you when you smoked a whole cigarette for the first time?”

16.06 (4.59)

“How old were you when you first smoked cigarettes daily or almost daily and at least for
2 months?”
“How old were you when the period of heaviest smoking started?”

18.59 (5.00)

“Do you still smoke or have you quit?”; if one replies “has quit”, then ask “When did you
last smoke (even a puff)?”; if one replies “Last puff >6 months ago”, then ask “How old
were you when you last smoked (even a puff)”?

46.14 (12.20)

“How many cigarettes do you/did you used to smoke per day?” 8 response categories (1–2,
3–5, 6–10, 11–15, 16–19, 20–25, 26–39, and 40 + ), original categorical observations
were replaced with class means of CPD (1.5, 3.5, 8, 13, 17.5, 22.5, 32.5, and 45 CPD,
respectively)
“What is the maximum number of cigarettes you have ever smoked during 1 day (24-h
period)?”
Sum score of three questions measuring sensation felt after smoking the first cigarette or
first puffs (“While smoking your very first cigarettes, did you (1) like the taste or smell of
the cigarette, (2) feel more relaxed, (3) feel a pleasurable rush or buzz?”) (range 1–10)
Sum score of seven questions measuring sensation felt after smoking the first cigarette or
first puffs (“While smoking your very first cigarettes, did you (1) cough, (2) feel dizzy or
light headed, (3) get a headache, (4) feel your heart racing, (5) feel nauseated, (6) feel
your muscles tremble or become jittery, (7) feel burning in your throat”?) (range 1–13)
Score based on (Heatherton et al. 1991) (range 0–10)

14.95 (9.25)

“After you smoked a whole cigarette for the first time, how long did it take until you
smoked another whole cigarette?) nine response categories ((A) never, (B) same day, (C)
next day, (D) within a week, (E) within a month, (F) within 3 months, (G) within 6 months,
(H) within a year, (I) after over a year); response alternatives were further categorized into
three categories: (2)= smoked the second cigarette same or next day, (1)= it took longer
than 1–2 days to smoke the second cigarette, (0)= never smoked another cigarette
The participants were queried about each DSM-IV nicotine withdrawal symptom: irritability,
restlessness, concentration problems, depressed mood, increased appetite, sleep problems,
nervousness, and decreased heart rate (Association 2000), within the context of a smoking
cessation. The reported symptoms were summed up to form a symptom score (range 0–8)

an exception, for smoking initiation we also included
another genotype-independent covariate, birth year, as the
age of smoking initiation of an individual may be affected
by the specific environment in his/her generation (Morabia et al. 2002). As a follow-up analysis, we then conducted another set of genome-wide time-to-event analyses
with additional transition-specific intermediate covariates
in order to obtain comparable results for the following
mediation analysis of significant SNPs, and to increase
the chance of detecting SNPs associated with the transitions independently of the intermediate covariates. We
evaluated biologically plausible covariates for each transition (selected based on literature and a priori knowledge
of factors affecting smoking behavior), and included those
significantly associated with the transition (P < 0.05)
(Table 2), as only significantly associated covariates are
eligible as candidate mediators.
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26.60 (9.93)

28.77 (14.41)
3.06 (2.66)

7.06 (2.61)

3.53 (2.39)
1.52 (0.51)

2.32 (2.08)

For smoking initiation, we considered positive and
negative first time sensations as these variables attempt
to capture the individual responses to the first-ever dose
of nicotine, and likely have a significant effect on the
probability of smoking a whole cigarette (Rios-Bedoya
et al. 2009).
For persistent smoking, we considered age at the first
cigarette, as it significantly affects the downstream steps
in smoking behavior (Breslau et al. 1993). Further, the
interval between the first and second cigarette was considered as an estimate of the initial speed of transition.
However, as the genome-wide analyses showed lack of
power, no follow-up analysis was performed.
For tolerance, we considered age of initiation of daily
smoking, as it is shown to predict earlier age at heaviest
smoking (Kendler et al. 2013). Further, we considered
CPD, max CPD ever smoked during a 24 h period, and
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Table 2. Basic characteristics of the datasets from the Finnish Twin cohort used in the four smoking behavior transition analyses.

Smoking
initiation

Start of
follow-up

End of
follow-up

Mean age at the
end of follow-up

Mean duration
in years2

Sample
size

Number of
families

Percentage
of males

Birth

Age at the
first cigarette

16.05  4.59

16.05  4.59

1615

701

56.6%

16.05  4.60

16.05  4.60

1530

688

56.9%

Tolerance

Age of daily
smoking

Age when
heaviest
smoking
started

26.59  9.92
26.59  9.92

8.10  9.57
8.10  9.57

1570
1570

719
719

57.4%
57.4%

Cessation

Age of daily
smoking

Age of quitting
or being
censored at
the date of
interview

38.85  11.45
38.64  11.39

20.23  11.19
20.29  11.15

1455
1431

708
704

56.8%
57.2%

Covariates1
Sex (P < 1e-10),
birth year (P < 1e-10)
Sex (P < 1e-10), positive
first time sensations
(P = 1.1e-03), negative
first time sensations
(P = 3.5e-07), birth year
(P < 1e-10)
Sex (P = 0.77)
Sex (P = 2.1e-08), CPD
(P = 4.4e-04), max CPD
(P = 1.2e-09), age of daily
smoking (P = 2.1e-08)
Sex (P = 0.014)
Sex (P = 1.2e-05), FTND
(P < 1e-10), DSM-IV
nicotine withdrawal
symptoms (P = 9.0e-03)

Binary outcome analysis using generalized linear mixed-effects model:

Outcome
Persistent
smoking

Daily smoking started
within 1 year (yes or no)
after the first cigarette3

Sample
size

Number of
families

Percentage
of males

15293
1522

711
710

57.6%
57.4%

Covariates1
Sex (P = 3.22e-05)
Sex (P = 0.025), age at the first cigarette (P = 8.7e-15),
interval between the first and second cigarette (P < 1e-10)

CPD, cigarettes per day; FTND, Fagerström Test for Nicotine Dependence; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th Edition.
The sample sizes for each transition analysis differ slightly because any subject with missing data on the corresponding phenotype or covariates
was excluded from the analysis of that transition.
1
P-values obtained from the coxme package or GLMM.
2
Censored individuals are not included in the computation of mean age at the end of follow-up and mean duration in year.
3
Out of the 1529 subjects, 450 proceeded to daily smoking within one year, while for 1079 subjects it took over a year. In our data set additional
37 subjects did not proceed to daily smoking during the follow-up period.

CPD at the period of heaviest smoking, as smoking quantity may affect the development of tolerance; rodent studies show that rapid tolerance is related to frequency of
nicotine administration and dose (Aceto et al. 1986).
For smoking cessation, we considered FTND and DSMIV nicotine withdrawal symptoms, as they likely affect the
ability to quit (Kozlowski et al. 1994).

Genotyping and quality control
Genotyping was performed at the Wellcome Trust Sanger Institute using the Human670-QuadCustom Illumina
BeadChip (N = 1104) and the Illumina Human Core
Exome BeadChip (N = 858). Pre-imputation exclusion
criteria for the data generated with the Human670QuadCustom Illumina BeadChip were minor allele frequency (MAF) < 0.01, sample and SNP call rate <0.95
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(<0.99 for SNPs with MAF < 0.05); and the criteria for
the data generated with the Illumina Human Core
Exome BeadChip were minor allele count <2, sample call
rate <0.98, SNP call rate <0.95 (<0.99 for SNPs with
MAF < 0.05). Both genotype datasets were filtered
according to the Hardy–Weinberg equilibrium (HWE)
test P < 1e-06. Further, sample heterozygosity test, gender, and Multidimensional Scaling (MDS) outlier checks
were done for both. Pre-phasing of the data was done
with SHAPEIT2 (Delaneau et al. 2013) and imputation
with IMPUTE2 (Howie et al. 2009) using the 1000 Genomes Phase I integrated haplotypes (produced using
SHAPEIT2) reference panel (1000 Genomes Project Consortium, 2012). Quality controls and imputation for the
GWAS data were done centrally at the Institute for
Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
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Statistical analyses
The genome-wide time-to-event analyses for smoking initiation, tolerance, and cessation were performed using the
Cox proportional hazards (PH) model (Cox 1972) with
random effects. We calculated the empirical kinship matrix
based on the observed relationship of family members, and
employed the coxme R package (Therneau 2012) which
implements the Cox PH model with random effects of
multivariate normal distribution by utilizing penalized partial likelihood (Ripatti and Palmgren 2000). The selected
sample with only one co-twin from each MZ pair and at
most one parent in each family resulted in a kinship matrix
in which individuals in a family share the same genetic correlation coefficient, dramatically reducing the computational time of the coxme function. For persistent smoking,
we found that over a quarter of individuals (N = 450)
became daily smokers within 1 year, and those who did
not engage in daily smoking within 20 years since initiation were considered as long-term survivors. In order to
account for this, we first adopted and implemented a mixture cure model to analyze this transition in the context of
survival framework (Yu and Peng 2008). The results, however, showed an inflated false positive error rate (data not
shown) probably due to the potential inaccuracy of the
variance estimation as shown in previous simulation studies (Yu and Peng 2008). We therefore addressed this issue
by dichotomizing the survival time variable and classified
those becoming a daily smoker within 1 year after smoking
the first cigarette as rapid progression (N = 450), and
those becoming a daily smoker after > 1 year as slow progression (N = 1079). We then conducted the association
analysis on this binary variable with the logistic linear
mixed effects model implemented in the glmmML R package (Brostr€
om and Holmberg 2011).
We performed the single-variant association analyses
only for those SNPs with a MAF > 5% and HWE test
P > 1e-05, and ensured that identified top signals had high
imputation information score (>0.8). The total number of
SNPs included in the genome-wide time-to-event analyses
was 5,918,992. We checked for potential population stratification by investigating the principal components for the
family founders with the EIGENSOFT package (Price et al.
2006); no outliers with foreign ancestry were found, as was
expected as the twin data consist purely of native Finnish
population. We adopted the genome-wide significance Pvalue of P < 5e-08 as a cutoff, which has been broadly recognized as a criterion based on the sequencing data of
European populations (Sham and Purcell 2014). For chromosomes containing loci exceeding the cutoff, we performed conditional analyses where we adjusted for the top
SNP to test whether the detected association represented
an independent signal. We list top five SNPs, regardless of
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their P-values, to allow for comparison with results from
the follow-up studies adjusting for the relevant covariates.
For SNPs identified as significantly associated with the
transitions, we further performed mediation analyses to
investigate whether the association is through plausible
mediators. Details of the mediation analyses are presented
in the Appendix S1. We used GWAVA (Ritchie et al. 2014)
for predicting the potential functional effects of the associating noncoding region SNPs.
For genome-wide significant signals, replication was
attempted for the top five SNPs as well as with all SNPs
within the nominated genes (with 50 kb flanking
regions). For the replication analyses, models identical to
those applied in the discovery sample were used. To
account for multiple testing, we applied a modified Bonferroni correction based on the effective number of independent SNPs in the gene regions calculated using a
formula proposed by Gao and colleagues (Gao et al.
2008; Hendricks et al. 2014).
We further conducted fixed-effect meta-analyses for the
top five SNPs based on the effect sizes and standard
errors from the discovery and replication studies using
GWAMA (http://www.well.ox.ac.uk/gwama). P-values
below 5e-08 were considered statistically significant.

Results
Genome-wide time-to-event analysis of
smoking initiation
The top five SNPs for the age at the first cigarette are
listed in Table 3. In the time-to-event analysis rs73050610
on 19q13.33 was highlighted (P = 1.12e-07) (Fig. S1,
Table 3). In a follow-up analysis additionally adjusted for
first time sensations rs73050610 achieved genome-wide
significance (P = 3.37e-08) (Fig. S2, Table 3). The LD
block in which all top five SNPs are located is flanked by
genes TRPM4 (1 kb apart) and SLC6A16 (60 kb apart). A
regional plot of the 19q13.33 locus is shown in Figure S3.
In an analysis conditioned on rs73050610, no residual
genome-wide significant signal remained, suggesting that
there is only one independent signal in this locus. The
hazard ratio (HR) of rs73050610 is 0.80, suggesting that
carriers of the minor allele have a 20% lower hazard per
allele of smoking the first whole cigarette.
None of the 19q13.33 top five SNPs showed statistically
significant evidence for replication in an independent
Australian twin family sample; however, the effect sizes
shared the same direction in analyses adjusted for first
time sensations. When attempting replication with all
SNPs located in TRPM4 and SLC6A16 (with 50 kb
flanking regions), statistically significant association was
seen in analyses adjusted for first time sensations for
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Table 3. The top five SNPs from the genome-wide time-to-event analyses.
CHR

BP

P

HR (or OR)

SNP ID

A1

A2

AF (CEU)

HWE

Smoking initiation with sex and birth year
19
49721561
1.116e-07
0.800
rs73050610
T
C
0.485 (0.441)
0.669
17
64169182
1.296e-07
1.676
rs75395715
C
T
0.056 (0.041)
0.683
19
49728893
2.475e-07
0.806
rs8105169
G
C
0.488 (0.435)
0.552
19
49727160
2.486e-07
0.806
rs8112298
T
C
0.488 (0.435)
0.562
19
49725042
2.531e-07
0.806
rs8103217
A
G
0.488 (0.435)
0.572
Smoking initiation with sex, birth year, positive and negative first time sensations
19
49721561
3.374e-08
0.783
rs73050610
T
C
0.485 (0.441)
0.669
19
49725042
6.256e-08
0.788
rs8103217
A
G
0.488 (0.435)
0.572
19
49727160
6.289e-08
0.788
rs8112298
T
C
0.488 (0.435)
0.562
19
49728893
6.307e-08
0.788
rs8105169
G
C
0.488 (0.435)
0.552
19
49728186
6.604e-08
0.788
rs3843746
C
T
0.489 (0.441)
0.587
Persistent smoking with sex
1
214682808
6.683e-06
1.837
rs6701211
G
A
0.088 (0.076)
0.515
17
1697361
6.909e-06
1.554
rs12941003
G
A
0.302 (0.429)
0.641
10
128564711
6.971e-06
1.562
rs4962638
G
A
0.750 (0.588)
0.607
14
96402039
8.570e-06
0.625
rs941777
A
T
0.828 (0.718)
0.333
14
96402810
9.585e-06
0.627
rs7155176
C
T
0.827 (0.718)
0.407
Persistent smoking with sex, age at the first cigarette, years between the first and second cigarettes
14
96402039
7.074e-06
0.592
rs941777
A
T
0.828 (0.718)
0.333
14
96404277
7.118e-06
0.594
rs1957126
T
C
0.827 (0.706)
0.467
14
96403278
7.580e-06
0.595
rs6575554
T
G
0.827 (0.706)
0.489
14
96402810
8.260e-06
0.595
rs7155176
C
T
0.827 (0.718)
0.407
14
96402094
8.691e-06
0.596
rs1957127
G
A
0.827 (0.718)
0.407
Tolerance with sex
11
32293139
1.294e-08
1.460
rs11031684
T
G
0.124 (0.153)
0.981
9
133510021
5.499e-07
1.251
rs2304808
T
C
0.251 (0.218)
0.343
6
91995475
5.825e-07
1.293
rs1884258
G
A
0.160 (0.076)
0.521
22
23058620
8.340e-07
1.386
rs9620160
A
G
0.129 (0.135)
0.567
9
133488447
1.481e-06
1.230
rs2304812
G
A
0.272 (0.235)
0.550
Tolerance with sex, age of daily smoking, CPD, and max CPD
9
133510021
3.811e-08
1.307
rs2304808
T
C
0.251 (0.218)
0.343
9
133490496
1.037e-07
1.306
rs7040341
G
T
0.237 (0.200)
0.164
9
133492544
1.318e-07
1.281
rs28476634
A
T
0.272 (0.235)
0.550
9
133488447
1.321e-07
1.281
rs2304812
G
A
0.272 (0.235)
0.550
9
133489452
1.424e-07
1.281
rs11795269
C
T
0.272 (0.235)
0.614
Cessation with sex
10
8841891
4.473e-08
1.479
rs72779075
C
A
0.207 (0.088)
0.587
10
8787478
1.028e-07
0.683
rs11255894
G
T
0.795 (0.731)
0.657
10
8838696
1.351e-07
1.457
rs7072531
C
T
0.210 (0.094)
0.386
10
8838279
1.374e-07
1.457
rs112340507
T
G
0.210 (0.094)
0.403
10
8791773
1.505e-07
0.688
rs1413687
A
T
0.792 (0.912)
0.336
Cessation with sex, DSM-IV nicotine withdrawal, FTND
10
8841891
1.829e-07
1.447
rs72779075
C
A
0.207 (0.088)
0.587
10
8838696
7.661e-07
1.419
rs7072531
C
T
0.210 (0.094)
0.386
10
8838279
7.850e-07
1.419
rs112340507
T
G
0.210 (0.094)
0.403
1
157267069
8.272e-07
0.689
rs6427366
T
A
0.781 (0.835)
0.682
10
8791773
9.169e-07
0.706
rs1413687
A
T
0.792 (0.912)
0.336

Info

Pr

HRr

Pm

0.983
0.863
0.998
0.999
0.999

0.899
0.602
0.910
0.918
0.921

1.005
0.942
1.004
1.004
1.004

4.170e-04
2.380e-04
1.187e-03
6.020e-04
4.630e-04

0.983
0.999
0.999
0.998
0.997

0.771
0.756
0.756
0.763
0.757

0.988
0.987
0.987
0.988
0.987

4.920e-05
8.400e-05
9.470e-05
9.590e-05
9.650e-05

0.997
0.800
0.994
0.995
0.996

NA1
NA1
NA1
NA1
NA1

NA1
NA1
NA1
NA1
NA1

NA
NA
NA
NA
NA

0.995
0.995
0.996
0.996
0.997

NA1
NA1
NA1
NA1
NA1

NA1
NA1
NA1
NA1
NA1

NA
NA
NA
NA
NA

0.838
0.984
0.996
0.919
1.000

NA2
0.161
0.404
NA2
0.266

NA2
1.051
0.958
NA2
1.038

NA
2.570e-05
3.262e-03
NA
1.260e-04

0.984
1.000
0.999
1.000
0.999

0.108
0.216
0.208
0.213
0.191

1.066
1.054
1.049
1.049
1.051

2.350e-06
1.190e-05
1.740e-05
1.690e-05
1.550e-05

0.994
0.941
0.989
0.989
0.991

0.380
0.214
0.236
0.245
NA2

1.084
0.910
1.099
1.096
NA2

1.220e-06
2.360e-06
2.440e-06
2.840e-06
NA

0.994
0.989
0.989
0.906
0.991

0.328
0.210
0.226
0.429
NA2

1.098
1.109
1.104
0.941
NA2

1.850e-06
4.980e-06
6.130e-06
4.760e-05
NA

CHR, chromosome; BP, base pair position according to build 37; P, P-value (P-values exceeding the genome-wide significance threshold [P < 5e-08]
are highlighted in bold); SNP ID, rs-number; A1, non-effect allele; A2, effect allele; AF, allele frequency of A2 observed in this study; CEU, allele frequency of A2 from the 1000 Genomes Project phase I of Utah Residents (CEPH) with Northern and Western European ancestry; HWE, Hardy–Weinberg Equilibrium test P-value; Info, measure of the observed statistical information associated with the allele frequency estimate (i.e., imputation info
score); Pr, P-value from the Australian replication study (rs11031684 failed imputation QC. Rs9620160 and rs1413687 were not available in the Australian 1000 Genomes imputed dataset); HRr, HR from the Australian replication study; Pm, P-value from the meta-analyses; CPD, cigarettes per day;
FTND, Fagerström Test for Nicotine Dependence; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th Edition.
1
Replication was not attempted as the association in the discovery sample was not genome-wide significant.
2
SNP not available in the replication sample.
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rs352813 (P = 9.2e-04, surpassing the significance threshold of P = 9.43e-04 based on the modified Bonferroni
correction), located 30 kb from the top SNP rs73050610
(Table S2). Rs352813 was not statistically significant in
the Finnish sample, and the direction of effect of
rs352813 was different in the Australian sample when
compared to the Finnish sample. Altogether 18 SNPs in
19q13.33 showed some association (P < 0.05) in both
populations. Meta-analysis of the top five SNPs did not
yield genome-wide statistically significant signals.
The estimated average causal mediation effects (ACME)
of rs73050610 through the positive and negative first time
sensations were 0.0213 (P = 0.70) (a positive coefficient
from the mediation analysis means that the hazard is
decreased. Refer to the Appendix S1 for the details of the
mediation analyses) and 0.0291 (P = 0.77), respectively,
suggesting that the effect of rs73050610 is not mediated
through the positive or negative first time sensations.

Genome-wide time-to-event analysis of
persistent smoking
The top five SNPs for the transition from the age at the
first cigarette to the age of daily smoking (rapid vs. slow
transition) are shown in Table 3. None of the SNPs
exceeded or approached the genome-wide significance
threshold. Manhattan and Q–Q plots are presented in
Figure S4. The Q–Q plots show deflated P-values indicating lack of sufficient statistical power, likely due to the
limited sample sizes for an association analysis with a binary variable. We did not pursue follow-up analyses or
attempt replication for this transition.

Genome-wide time-to-event analysis of
tolerance
The top five SNPs for the transition from daily smoking
to heaviest smoking are presented in Table 3. In the
time-to-event analysis rs11031684 on 11p13 showed genome-wide significant association (P = 1.29e-08) (Fig. S5,
Table 3) with an HR of 1.46, suggesting that the minor
allele accelerates the progression to tolerance. This SNP is
located in a pseudogene RP1-65P5.1, and is flanked by
RCN1 and WT1 within a distance of approximately
150 kb. A regional plot of the 11p13 locus is shown in
Figure S6. In an analysis conditioned on rs11031684, no
residual genome-wide significant signal remained, suggesting that there is only one independent signal in this locus.
In a follow-up analysis additionally adjusted for age of
daily smoking, CPD, and max CPD, rs2304808 residing in
FUBP3 on 9q34.12 showed genome-wide significant association (P = 3.81e-08) (Fig. S7, Table 3) with an HR of
1.31, suggesting that carriers of the minor allele progress
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more quickly to tolerance. A regional plot of the 9q34.12
locus is shown in Figure S8. In an analysis conditioned
on rs2304808, no residual genome-wide significant signal
remained, suggesting that there is only one independent
signal in this locus. None of the top five SNPs replicated
in an independent Australian twin family sample, nor did
any SNPs located within RP1-65P5.1, WT1, RCN1, or
FUBP3. Meta-analysis of the top five SNPs did not yield
genome-wide statistically significant signals.
The estimated ACME of rs11031684 through CPD and
max CPD were 0.525 (P = 0.04) and 0.619
(P = 0.07), respectively, suggesting that some of the
effects of rs11031684 is mediated through CPD. Additionally, we found that rs11031684 was nominally associated
with CPD (P = 0.0084) and max CPD (P = 0.0062). The
estimated ACME of rs2304808 through CPD and max
CPD were 0.231 (P = 0.22) and 0.304 (P = 0.24), respectively, suggesting that the effect of rs2304808 is not mediated through CPD or max CPD.

Genome-wide time-to-event analysis of
cessation
The top five SNPs for the transition between daily smoking
and cessation are presented in Table 3. In the time-toevent analysis rs72779075 on 10p14 showed genome-wide
significant association (P = 4.47e-08) (Fig. S9, Table 3)
with an HR of 1.48, suggesting that carriers of the minor
allele quit earlier than noncarriers. In a follow-up analysis
additionally adjusted for FTND and DSM-IV nicotine
withdrawal symptom score, rs72779075 remained as the
top SNP but the signal no longer was significant (Fig. S10,
Table 3). This locus is close to a pseudogene RP11-575N15
(with a distance of <40 kb), and the nearest gene is GATA3
(725 kb apart). A regional plot of the 10p14 locus is shown
in Figure S11. In an analysis conditioned on rs72779075,
no residual genome-wide significant signal remained, suggesting that there is only one independent signal in this
locus. None of the top five SNPs replicated in an independent Australian twin family sample, nor did any SNPs
located within GATA3. Meta-analysis of the top five SNPs
did not yield genome-wide statistically significant signals.
The estimated ACME of rs72779075 through FTND
and DSM-IV nicotine withdrawal symptoms were
4.1744 (P = 0.15), and 0.25967 (P = 0.55), respectively, suggesting that the effect of rs72779075 is not
mediated through ND or nicotine withdrawal symptoms.

Investigation of previously highlighted
smoking-related genes
To scrutinize whether previously identified smokingrelated genes affect the transitions in the Finnish sample,
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we investigated common variants (MAF > 5%) surpassing
our quality control thresholds from seven relevant gene
regions (CHRNA5-CHRNA3-CHRNB4 gene cluster,
CYP2A6, DRD2, DRD4, DBH, CHRNA4, and BDNF). Multiple SNPs in each gene region were nominally associated
(P < 0.05) with at least one of the transitions (Table S3)
although some well-known SNPs, such as rs16969968 in
CHRNA5, showed no association (P > 0.05) with the transitions, although suggestive association was detected with
CPD (P = 0.012) and FTND (P = 0.0001). Furthermore,
SNPs in DBH were involved in all four transitions, and
rs6011794 in CHRNA4 was associated with initiation
(P = 0.0469), tolerance (P = 0.0217), and cessation
(P = 0.0331). Rs2086484 in CHRNB4, rs1611121 in DBH,
and seven SNPs (rs144298540, rs62206942, rs117589312,
rs59073906, rs58253278, rs112265183, and rs116920489) in
CHRNA4 showed evidence of association with two transitions. Two SNPs (rs7260629 in CYP2A6 and rs75298795 in
BDNF) associated with initiation (P = 2.45e-03) and tolerance (P = 2.42e-03), respectively, with P-values surpassing
the significance thresholds (P = 2.94e-03 and P = 2.78e-03,
respectively) based on the modified Bonferroni correction.

Discussion
The progression of smoking behavior from initiation to
persistent smoking or cessation is a complex process
involving multiple factors. Although some of the genetic
factors related to smoking quantity and ND have been
identified, we have only began to understand the underlying genome-wide genetic effects on the development of
smoking behavior. In this study, we identified novel SNPs
associated with three specific transitions in smoking
behavior in a Finnish twin family sample (N = 1962).
Considering age at smoking initiation we found that
Finnish Twin Cohort subjects born at later decades began
smoking at younger age compared to subjects born at
earlier decades, which is consistent with a previous Swiss
study (Morabia et al. 2002), and that females started
smoking later than males, which is also in accordance
with previous findings (Okoli et al. 2013). This is also
consistent with the evolution of tobacco use in Finland in
the 20th century. Although the Q–Q plots (Figs S1 and
S2) suggest that the family correlation structure was well
controlled for, a mild overdispersion is observed. This
implies that common environmental factors may also play
a role in smoking initiation even after adjusting for birth
year. DZ twins share more environmental factors than
non-twin members of a family, and this environmental
correlation structure is not captured by the used kinship
matrix, which may lead to slight P-value inflation.
In the time-to-event analysis of age at smoking initiation adjusted for first time sensations, multiple SNPs on
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19q13.33, flanked by TRPM4 and SLC6A16, were highlighted in both the Finnish sample and the independent
Australian sample. The highlighted SNPs from the two
studies differed but intertwined with each other, providing motivation for further investigating the involvement
of nearby genes in smoking initiation. The associating
SNPs seem to have a heterogeneous effect. The top five
SNPs from the Finnish sample showed no statistically significant association in the Australian sample although
they shared the same direction of effect. On the other
hand, in the replication sample, a SNP on 19q13.33,
located 30 kb from the top SNP in the Finnish sample,
showed association adjusted for multiple testing, with a
direction of effect opposite from that seen in the Finnish
sample. The heterogeneous effects of these markers may
reflect variation in LD block structures (Rosenberg et al.
2010) or be due to gene-environment interactions which
substantially amplify the difference of SNP effects, and
may suggest that these population-specific interactions
play a critical role in the complex behavioral phenotypes,
as previously suggested (Adeyemo and Rotimi 2010; Ho
et al. 2010).
First time sensations plausibly affect the probability of
smoking a whole cigarette; in line with this, in our study
sample positive and negative first time sensations are
associated with earlier and later age of initiation, respectively. In order to evaluate whether the association on
19q13.33 was independent of first time sensations, we
included them as covariates in the follow-up analysis, and
detected genome-wide significant association. Further,
mediation analysis confirmed that the effect of the top
SNP, rs73050610, is independent of first time sensations,
and thus the effect is likely due to other mechanisms
besides the initial sensations experienced after the firstever dose of nicotine. The functional annotation with
GWAVA suggests that rs3843746, which is in complete
LD with rs73050610 in the Finnish population (D0 = 1.00,
r2 = 0.979), is a CTCF-binding region variant. CTCF is
involved in multiple regulatory influences on expression
of genes, suggesting that the highlighted SNP may have a
role in regulating nearby genes. Both of the flanking genes
have functions relevant for smoking behavior. TRPM4 is
a calcium-activated ion channel involved in many activities including immune response (Guinamard et al. 2010),
and is the key gene encoding the channel for most calcium-activated nonselective cationic currents (Ican)
observed in native tissues (Mrejeru et al. 2011). Ican are
involved in the generation of tonic and bursting activity
in dopamine neurons (Mrejeru et al. 2011), and the burst
firing is proposed to encode a “reward” signal during
habit learning and pathological addictions (Phillips et al.
2003). Thus, variants in TRPM4 may affect smoking
behavior through the dopaminergic system.
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The other flanking gene, SLC6A16, is a member of the
Na+/Cl dependent neurotransmitter transporter gene
family (Farmer et al. 2000), and little is known about its
substrates and functional significance. Another member of
the solute carrier gene group, SLC17A7, located 211 kb
from rs73050610, is a vesicular glutamate transporter previously found to be induced by smoking (Flatscher-Bader
et al. 2008). Blockade of glutamatergic transmission inhibits the rewarding-enhancing effects of nicotine, thus
reducing nicotine-seeking behavior (Li et al. 2014). Alterations in glutamatergic neurotransmission are involved in
several psychiatric disorders, such as schizophrenia and
alcohol dependence (Shigeri et al. 2004; Comasco et al.
2014), which also influence smoking behavior; however,
in this study we did not assess comorbid psychiatric disorders. Inclusion of such phenotypes in future studies
would allow scrutiny of potential pleiotropic effects.
Our analyses of persistent smoking indicate that being
a female, smoking the first cigarette at a later age, and
having a longer interval between the first and the second
cigarette predicts later onset of daily smoking. We
detected no genome-wide significant associations for the
transition from the age of smoking the first cigarette to
the age when daily smoking started. We likely had insufficient power in the analysis of the binary variable (rapid
vs. slow transition) especially when using the mixed
effects model. Larger samples are needed to investigate
the transition to daily smoking.
Our analyses of tolerance indicate that being a woman
and smoking less are related to slower progression to tolerance, while later age of daily smoking predicts acceleration.
In the time-to-event analysis, we detected a genome-wide
significant association with rs11031684 residing on 11p13
in a pseudogene RP1-65P5.1, and located 100 kb downstream of WT1. WT1 is a transcription factor involved in
the regulation of human cell growth and differentiation,
and is an established tumor suppressor gene. Exposure to
heavy smoking influences the methylation pattern of CpG
islands in WT1 (Bruno et al. 2012), providing a plausible
mechanism for smoking induced cancers. In addition to
affecting methylation, heavy smoking is suggested to affect
the development of tolerance (Aceto et al. 1986). In order
to evaluate whether the detected association was independent of smoking quantity, we included measures of smoking quantity as covariates in the follow-up analysis. The
signal on 11p13 no longer was significant at a genomewide level (P = 4.04e-06); further, mediation analysis suggested that rs11031684 affects the hazard of progression to
tolerance partly through smoking quantity. Interestingly,
in the follow-up analysis a novel genome-wide significant
signal emerged for rs2304808 on 9q34.12 within FUBP3,
which belongs to a family of homologous gene-regulatory
proteins that regulate many common target genes. Media-
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tion analysis further confirmed that the effect of rs2304808
was not mediated through smoking quantity. Inclusion of
smoking quantity as a covariate substantially increased the
significance of rs2304808, suggesting that including intermediate covariates may increase the power to detect SNPs
that are independent of the covariates and directly associated with the phenotype.
In the analysis of smoking cessation we found that being
a female, scoring higher in ND, and stronger nicotine withdrawal symptoms predicts slower transition to quitting,
whereas later age of daily smoking predicts faster quitting.
In the time-to-event analysis we detected genome-wide significant association with rs72779075 on 10p14, located
35 kb from a pseudogene RP11-575N15 and around
725 kb downstream of GATA3. In the follow-up analysis
the signal of this SNP was no longer significant; however,
our mediation analysis showed no statistically significant
evidence for the effect of rs72779075 being mediated by
ND or nicotine withdrawal symptoms, and thus the effect
on difficulty in achieving and maintaining abstinence is
likely due to other mechanisms besides the severity of ND
and withdrawal. Interestingly, nicotine upregulates expression of GATA3 through stimulation of nAChRs (Arredondo et al. 2006). GATA3 is crucial in inducing allergic
airway inflammation (Barnes 2008); although rs72779075
is located 725 kb downstream of GATA3, it may tag variants that influence symptoms of airway inflammation and
thus may motivate smokers to quit. Alternatively, RP11575N15 may have an unidentified function. Transcripts
produced from pseudogenes may, for example, regulate the
effects of microRNAs on their targets by competing for
microRNA binding (Swami 2010).
Although our data included an extraordinarily detailed
smoking history, there are still some limitations in our
study. Smoking behavior encompasses psychiatric and
social behaviors in which both complex genetic and environmental factors are involved; these were not accounted
for in our analyses. Also other plausibly relevant covariates, such as socio-economic status, and working environment, were not considered. Further, our phenotype data
were collected retrospectively in subjects with a mean age
of 56 years at the time of the interview; thus the accuracy
of self-reported ages of onsets may be influenced by recall
bias. Although the interviews contained detailed measures
of ND, the age of onset of ND was not assessed, and thus
we were not able to perform time-to-event analyses of
ND. However, we analyzed tolerance, which is the key
dimension of ND. The efficient long-term survival model
accounting for family structure, which to the best of our
knowledge is not available, would be more appropriate
when analyzing the transitions to daily smoking and quitting, and it should be considered in the future. Future
studies should also attempt to investigate low-frequency
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variants (MAF < 0.05) in the context of transitions in
smoking behavior.
The lack of replication may implicate false positive findings. Alternatively, it may be due to lack of power in the
replication sample, population specificity of the associations, as well as gene-environment interactions. In addition, our study sample comes from one of the bestcharacterized founder populations, the Finns. Unique LD
patterns are observed in founder populations (Service et al.
2006); thus, the lack of replication may at least partly be
due to the genetic heterogeneity between the discovery
sample (Finns) and replication sample (Australians). It has
been shown that population isolates, especially those
founded recently, such as Finland, have longer stretches of
LD than outbred populations and may thus achieve better
genome-wide coverage with equivalent numbers of markers (Peltonen et al. 2000; Service et al. 2006). Our top
SNPs may tag underlying functional variants in the Finnish
sample, but due to differences in LD structures the functional variants are not necessarily captured by these SNPs
in the Australian data. Population-specific functional variants are known to exist (Lim et al. 2014), and one has
already been documented in the Finnish population for a
behavioral trait (Bevilacqua et al. 2010).
The advantages of this study include the detailed phenotype profiles, allowing us to more precisely handle the
complexity of the smoking behavior phenotype, which
has previously been modeled in a relatively static way
(e.g., ever vs. never smoker). This approach to phenotype
refinement may help to identify novel signals, and perhaps be tractable with smaller samples than conventionally required. Our novel results suggest that the various
stages in smoking history are affected by different underpinning mechanisms. Complex neurotransmitter networks
including dopamine and glutamate may play a critical
role in initiation, while airway inflammation possibly contributes to smoking cessation.
In conclusion, we detected genome-wide significant
association between SNPs and three transitions in smoking behavior in a Finnish twin family sample. The interpretation of our findings should be cautious before
robust evidence of replication is obtained. Our results are
valuable for guiding follow-up functional analyses, provide valuable clues into the etiology of smoking behavior,
and encourage further studies utilizing time-to-event phenotypes in addictive behavior.
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Supporting Information
Additional supporting information may be found online
in the supporting information tab for this article:
Figure S1. (A) Manhattan and (B) Q–Q plots for the
genome-wide time-to-event analysis of smoking initiation
(adjusted for sex and birth year) (k = 1.083).
Figure S2. (A) Manhattan and (B) Q–Q plots for the
follow-up analysis of smoking initiation (adjusted for sex
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and birth year, as well as positive and negative sensation
scores) (k = 1.089).
Figure S3. Regional plot of the 19q13.33 locus
rs73050610 identified for smoking initiation (data from
analysis adjusted for sex and birth year, as well as positive
and negative sensation scores).
Figure S4. (A) Manhattan and (B) Q–-Q plots for the
genome-wide time-to-event analysis of persistent smoking
(adjusted for sex) (k = 1.002).
Figure S5. (A) Manhattan and (B) Q–Q plots for the
genome-wide time-to-event analysis of tolerance (adjusted
for sex) (k = 1.027).
Figure S6. Regional plot of the 11p13 locus rs11031684
identified in the genome-wide time-to-event analysis of
tolerance (data from analysis adjusted for sex).
Figure S7. (A) Manhattan and (B) Q–Q plots for genome-wide time-to-event analysis of tolerance (adjusted
for sex, age of daily smoking, CPD, and max CPD)
(k = 1.078).
Figure S8. Regional plot of the 9q34.12 locus rs2304808
identified in the genome-wide time-to-event analysis of
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tolerance (data from analysis adjusted for sex, age of daily
smoking, CPD, and max CPD).
Figure S9. Manhattan and Q–Q plots for the genomewide time-to-event analysis of cessation (adjusted for sex)
(k = 1.001).
Figure S10. Manhattan and Q–Q plots for the genomewide time-to-event analysis of cessation (adjusted for sex,
FTND, and DSM-IV nicotine withdrawal) (k = 1.011).
Figure S11. Regional plot of the 10p14 locus rs72779075
identified in the genome-wide time-to-event analysis of
cessation (data from analysis adjusted for sex).
Table S1. Description of the NAG-OZALC sample used
for replication.
Table S2. Results of the replication study for SNPs
located in TRPM4 and SLC6A16 (with 50 kb flanking
regions). For comparison, corresponding results from the
Finnish discovery sample are also shown.
Table S3. List of SNPs in smoking-related genes reported
from previous GWAS that show nominal association
(P < 0.05) with the transitions.
Appendix S1. Details of the mediation analyses.
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